Stephanie Tomasek
Family · Belton, TXNPI 1730385261
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novo Nordisk at 30.3% of the total. Reporting peaked in 2021 at $806 and has fallen 50.4% since, to $400 in 2025.
Across 72 payments — averaging $23.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$516
- Lilly USA, LLC$247
- Medtronic$148
- Teva Pharmaceuticals USA, Inc.$133
- Boehringer Ingelheim$108
- Abbott$83
- plus $467 from 15 others
What the payments were for
- Food & beverage$1,69099%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $516 |
| Lilly USA, LLC | 13 | $247 |
| Medtronic | 1 | $148 |
| Teva Pharmaceuticals USA, Inc. | 2 | $133 |
| Boehringer Ingelheim | 2 | $108 |
| Abbott | 4 | $83 |
| AbbVie | 3 | $64 |
| Pfizer | 4 | $64 |
| Biohaven Pharmaceuticals, Inc. | 3 | $47 |
| Genentech USA, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Amgen | 2 | $31 |
| GSK | 2 | $30 |
| AstraZeneca | 2 | $30 |
| Exact Sciences | 1 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| KCI USA, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Novartis | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,702 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProgesteroneProgesterone, Micronized | 32 | $1,159 |
| Eszopiclone | 11 | $237 |
| Levothyroxine Sodium | 21 | $173 |
| Tizanidine Hcl | 11 | $151 |
| Montelukast Sodium | 17 | $135 |
| Carvedilol | 15 | $69 |
| Tramadol Hcl | 12 | $39 |
| Verapamil Hcl | 14 | $32 |
| Losartan Potassium | 12 | $19 |
Paid to pharmacies, not to this prescriber.
Other family in Belton
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.